---
title: "603087.SH (603087.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/603087.SH/news.md"
symbol: "603087.SH"
name: "603087.SH"
parent: "https://longbridge.com/en/quote/603087.SH.md"
datetime: "2026-05-21T05:48:51.167Z"
locales:
  - [en](https://longbridge.com/en/quote/603087.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603087.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603087.SH/news.md)
---

# 603087.SH (603087.SH) — Related News

### [Gan & Lee's insulin has been approved by the EU, marking three successes in six months as it begins its overseas expansion](https://longbridge.com/en/news/286572293.md)
*2026-05-15T13:03:19.000Z*
> Gan & Lee's Lai Pro Insulin Injection (Bysumlog®) has obtained marketing authorization in the European Union, marking an

### [Gan & Lee: Liraglutide insulin injection has obtained marketing authorization from the European Commission](https://longbridge.com/en/news/286383517.md)
*2026-05-14T08:33:04.000Z*
> Gan & Lee and its wholly-owned subsidiary Gan & Lee Europe recently received approval from the European Commission for t

### [Gan & Lee: Insulin Aspart Injection has obtained marketing authorization from the European Commission](https://longbridge.com/en/news/285347198.md)
*2026-05-06T09:32:04.000Z*
> Gan & Lee Pharmaceutical and its wholly-owned subsidiary Gan & Lee Pharmaceutical Europe GmbH recently obtained listing 

### [Where is Gan & Lee's new track?](https://longbridge.com/en/news/284989986.md)
*2026-05-03T09:24:23.000Z*
> Gan & Lee achieved operating revenue of 4.052 billion yuan in 2025, a year-on-year increase of 33.06%, and a net profit 

### [Gan & Lee: Plans to distribute 10 yuan for every 10 shares in the fiscal year 2025, with multiple proposals pending review](https://longbridge.com/en/news/284718566.md)
*2026-04-30T07:44:43.000Z*
> Gan & Lee announced that the 2025 annual shareholders' meeting will be held on May 13, 2026, to review multiple proposal

### [Guotai Junan Securities: Innovation is Key in the Post-Procurement Era, Focus on Investment Opportunities in Domestic New Drugs](https://longbridge.com/en/news/284290232.md)
*2026-04-28T01:23:17.000Z*
> Guojin Securities released a research report indicating that under the normalization of centralized procurement, domesti

### [Gan & Lee: The first subject has been dosed in the Phase III clinical trial for the new indication of Bofavine Glutide Injection](https://longbridge.com/en/news/283799940.md)
*2026-04-23T09:22:12.000Z*
> Gan & Lee announced that its wholly-owned subsidiary, Gan & Lee Pharmaceutical Shandong Co., Ltd., has independently dev

### [Gan & Lee: Net profit of 1.144 billion yuan in 2025, a year-on-year increase of 86.05%](https://longbridge.com/en/news/283644733.md)
*2026-04-22T10:25:29.000Z*
> Gan & Lee announced that the operating revenue for 2025 is expected to be 4.052 billion yuan, a year-on-year increase of